Majority of patients with reflux disease do not have higher risk of cancer, study reports

Reflux disease manifests as acid regurgitation and heartburn and is a known risk factor for esophageal cancer.

House lawmakers float transparency reforms for 340B program at hearing

WASHINGTON – House lawmakers on Tuesday floated reforms to a controversial drug discount program serving low-income populations, but it’s still unclear which policies will come

June 5, 2024

Lyell Immunopharma to acquire ImmPACT Bio, cut top programs

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

October 26, 2024

Immunic Reports Positive Interim Data from Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis – Biotech Investments

Issuer: Immunic, Inc. / Key word(s): Study results 09.10.2023 / 22:01 CET/CEST The issuer is solely responsible for the content of this announcement. Immunic Reports

October 10, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.